Neil Kumar, BridgeBio CEO
November 18, 2021 10:27 AM ESTUpdated 10:59 AM
Financing

Bridge­Bio bor­rows $750M ahead of key PhI­II read­out, as it looks to wrap up buzzy 2021

Max Gelman

Senior Editor

The way Bridge­Bio tells it, it’s been up to some big things re­cent­ly. And on Thurs­day, the biotech just got a whole lot more cash …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times